At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
capecitabinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Jan 11, 2006·Updated Jan 27, 2020
In Brief
A Phase 2 clinical trial evaluating capecitabine for Breast Cancer. Completed, enrolled 26 participants across 3 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well capecitabine works in treating patients with metastatic breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2004
First PostedJan 2006
Primary CompletionDec 2009
Study CompletionNov 2012
TodayJul 2026
First PostedJan 11, 2006
Enrollment StartApr 1, 2004
Primary CompletionDec 1, 2009
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 20.5 years ago
Interventions
capecitabinedrug
A total of 115 cycles of therapy were administered and five patients did not complete cycle 1. The median number of cycles initiated was four (range 1-16).